Sino Biopharmaceutical Limited (SBHMY) Fair Value & Analysis
Healthcare · US · Market cap $10.1B
Sino Biopharmaceutical Limited
SBHMY · US
Fair value as of: Jul 18, 2026
From 26 valuation models · updated 7 days ago
Fair value updated Jul 18, 2026, revised from $9.84 to $8.31 (−15.5%) since Jun 24, 2026. Share price +12.5% over the past month.
Price vs Fair Value (12 months)
12‑month range $7.29 – $20.16 · fair‑value band $6.23 – $10.39 · the $12.68 price screens above the $8.31 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Sino Biopharmaceutical Limited (SBHMY) currently trades at $12.68, while our model-based Fair Value estimate is $8.31, implying the stock looks roughly 34.5% overvalued today. We read business quality at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Sino Biopharmaceutical Limited generated revenue of $31.8B at a net margin of 7.4%. Revenue grew 9.8% year over year. It earns a return on equity of 12.5%. Net debt stands at $3.9B. Fundamentals as of Jul 18, 2026
Our scenario range runs from $6.23 (bear case) to $10.39 (bull case); at $12.68, the current price sits above that range. The share trades about 37% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside, at -34%, SBHMY screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sino Biopharmaceutical Limited reported revenue of $31.0B in FY2025 versus $26.9B in FY2021, a compound +3.6%/yr. Reported net income was $2.3B in FY2025, compounding −37.1%/yr from FY2021.
Is SBHMY fairly valued? → Check now
Recent news
- European Stocks Close Sharply Lower in Wednesday Trading; Oil Prices Spike as US-Iran War Reignites
- AstraZeneca to pay $200M upfront for Sino Biopharmaceutical’s COPD drug license deal
- GSK plc (GSK) Announces Japan’s Expanded Eligible Population for Arexvy
- GSK’s Expanded Arexvy Label And Deals Add Context To Valuation Gap
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 167,300 KRW | 76,382 KRW | -54% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| WuXi Biologics (Cayman) Inc 2269 | HK$32.74 | HK$24.99 | -24% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
| Genmab A/S GMAB | kr 1,608 | kr 237.22 | -85% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Sino Biopharmaceutical Limited (SBHMY) undervalued?
What is the fair value of SBHMY?
What is the quality score of SBHMY?
What is the revenue of Sino Biopharmaceutical Limited (SBHMY)?
What is the net profit margin of SBHMY?
Does Sino Biopharmaceutical Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Sino Biopharmaceutical Limited analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.